D.E. Shaw & Co
ALGS icon

D.E. Shaw & Co’s Aligos Therapeutics ALGS Stock Holding History

D.E. Shaw & Co’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81.6K Buy
+10,978
New +$83.3K ﹤0.01% 4302
2022
Q4 		– Sell
-1,263
Closed -$35K – 4837
2022
Q3 		$35K Sell
1,263
-4,932
-80% -$164K ﹤0.01% 4732
2022
Q2 		$187K Buy
6,195
+5,364
+645% +$182K ﹤0.01% 4568
2022
Q1 		$45K Buy
+831
New +$66.5K ﹤0.01% 5161

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

D.E. Shaw & Co's ALGS Position: Q1 2026 in Review

D.E. Shaw & Co opened a new position in Aligos Therapeutics (ALGS) in Q1 2026: 10,978 shares worth $81.6K. The stake represents ﹤0.01% of the portfolio and ranks #4302 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in ALGS as recently as Q3 2022.

D.E. Shaw & Co first reported a position in ALGS in Q1 2022 and has held it in 4 quarters since. The position peaked at $187K in Q2 2022. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • D.E. Shaw & Co held 10,978 shares of Aligos Therapeutics worth $81.6K as of Q1 2026.
  • Aligos Therapeutics was a new D.E. Shaw & Co position in Q1 2026.
  • Aligos Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4302 holding.
  • D.E. Shaw & Co first reported a position in Aligos Therapeutics in Q1 2022 and has held it in 4 quarters since.
  • D.E. Shaw & Co's Aligos Therapeutics position peaked at $187K in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.